GlassScriptPhysician profile
Bert M Stewart
NPI 1508965518
$1,319.63
in general payments reported to CMS, 2019-2025
25 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.08 · 2020: $31.22 · 2021: $88.31 · 2022: $448 · 2023: $202 · 2024: $152 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $236.04 | 2022-2025 | Cimzia, Bimzelx |
| Heron Therapeutics, INC. | $223.19 | 2022-2025 | Zynrelef |
| Csl Behring | $132.70 | 2019-2024 | Hizentra |
| Janssen Biotech, INC. | $122.47 | 2022-2024 | Simponi Aria, Remicade, Simponi |
| Fujifilm Healthcare Americas Corporation | $79.25 | 2022 | |
| Microline Surgical INC | $66.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $50.70 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.00 | 2022-2023 | Evusheld |
| Alexion Pharmaceuticals, INC. | $38.72 | 2019 | |
| Davol INC. | $31.22 | 2020 | |
| Argenx US, INC. | $29.98 | 2025 | Vyvgart Hytrulo |
| Sandoz INC. | $26.55 | 2025 | Jubbonti |
| Celgene Corporation | $25.83 | 2024 | Orencia |
| Innovation Technologies INC | $21.85 | 2023 | Irrisept |
| Ethicon US, LLC | $21.12 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $21.01 | 2022 | |
| Tanabe Pharma America, INC. | $20.16 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $19.30 | 2024 | Arcalyst |
| Amgen INC. | $19.05 | 2022 | |
| Genzyme Corporation | $17.69 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.95 | 2019 | |
| Lilly USA, LLC | $16.73 | 2025 | Zepbound |
| Abbvie INC. | $16.44 | 2025 | |
| Organogenesis INC. | $15.68 | 2025 | Puraply Wound Matrix |
| Acorda Therapeutics, INC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bert Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.